Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16478255 | 0.85 | NPC1 (0.35) | PDE10ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26207348 | 0.77 | MAOA (0.37) | ALDH1A1 | |
| SCHEMBL28906398 | 0.76 | CYP3A4 (0.39) | ALDH1A1GAA | |
| SCHEMBL29679938 | 0.76 | HSD17B10 (0.39) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL31243002 | 0.76 | CYP3A4 (0.39) | ALDH1A1GAA | |
| SCHEMBL23043132 | 0.76 | HSD17B10 (0.39) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL28221164 | 0.76 | SELL (0.39) | KMT2AALDH1A1POLBKDM4ENPC1 | |
| SCHEMBL31527295 | 0.72 | TRPV4 (0.35) | — | |
| SCHEMBL31527534 | 0.72 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL31527207 | 0.72 | RECQL (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023039240-A9 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-06-01 | — | — | WO | disclosed |